FDA clears Radiopharm Theranostics’ (ASX: RAD) IND for Phase 2b brain metastases imaging study

July 23, 2024 11:01 AM AEST | By Sonal Goyal

FDA clears Radiopharm Theranostics’ (ASX: RAD) IND for Phase 2b brain metastases imaging study — Image source: Company update

Recent News

Entertainer Tori Martin Gets 'Lost In The Country' In New Music Video

TECNO Wins Two Gold Awards at Global Product Technology Innovation Awa...

Melbourne Asphalts and Bitumen Expands Service Offerings for Melbourne...

Come to RE+2024 to discover the cutting-edge energy solutions of tomor...

Highlights

US FDA clearance has been received for the Investigational New Drug (IND) application for RAD 101.

The FDA IND approval marks a significant milestone towards commencing the Phase 2b imaging trial in brain metastases.

First patient dosing is expected during the fourth quarter of 2024.

Radiopharm Theranostics Limited (ASX:RAD) has achieved a significant milestone with the clearance of its IND application for F18-Pivalate (RAD 101) by the US FDA. This approval paves the way to start the Phase 2b multi-centre trial aimed at imaging brain metastases.

The IND approval demonstrates clear recognition of the clinical data already generated for RAD 101 by the US FDA.

The company expects to dose first patient in the fourth quarter of 2024 and the 30-patient Phase 2b read-out is anticipated by mid-2025, based on the current enrolment expectations.

Following this, the company plans to proceed with a Phase 3 registrational study

About F18-Pivalate

Pivalate is a small molecule designed to selectively target fatty acid synthetase, an enzyme that exhibits elevated expression levels in brain tumours remains at normal levels in healthy cells. Clinical investigation is currently underway for this novel proprietary imaging agent aimed at identifying and characterising brain metastases.

The Phase 2a imaging trial of Pivalate, conducted at the Imperial College of London, yielded positive results. The trial involved 17 patients with brain metastases and demonstrated significant tumour uptake consistent across various tumour origins. These findings demonstrate the potential of Pivalate as a valuable tool for monitoring brain metastases.

Radiopharm has secured a worldwide license for the pivalate platform technology. The company is actively partnering with the Imperial College of London on developing a therapeutic candidate that operates through the same mechanism of action.

RAD share performance

RAD shares traded at AU$0.039 apiece, up 2.6%, at the time of writing on 23 July with a market cap exceeding AU$40 million.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.